Brand-Ad-30-6
 IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3983 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed8705    
    Printed214    
    Emailed6    
    PDF Downloaded329    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 

 STUDIES
Year : 2004  |  Volume : 70  |  Issue : 2  |  Page : 92--95

An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris


1 Department of Dermatology, G. T. Hospital, Mumbai, India
2 Department of Dermatology, Rajiv Gandhi Medical College, Kalwa, Thane, India
3 Consultant Dermatologist, Pramila Hospital, Kalwa, Thane, India
4 Consultant Dermatologist, B. R. Hospital, Chennai, India
5 Department of Dermatology, Stanley Medical College and Hospital, Chennai, India
6 Consultant Dermatologist, Indus Hospital, Mohali, India
7 Glenmark Pharmaceuticals Ltd, Mumbai, India

Correspondence Address:
Neelesh Dongre
Manager - Medical Services, Glenmark Pharmaceuticals Ltd., 801-813, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400026
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17642573

Rights and PermissionsRights and Permissions

BACKGROUND: Tazarotene is a new third generation topical acetylenic retinoid. The present study was conducted to evaluate the efficacy and safety of tazarotene gel (0.1%) in Indian patients of acne vulgaris. METHODS: The present study was a prospective, open, multicentric, phase III trial. The duration of study was 14 weeks, including a 12-week active treatment period, preceded by a 2-week washout phase. Patients applied 0.1% tazarotene gel as a thin film over the affected area once daily in the evening. The efficacy was evaluated by analyzing changes in the number of facial acne lesions and patient's and physicians' global assessment. The efficacy parameters were assessed at baseline, visits 2, 4, 8, and 12 weeks. Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events. RESULTS: A total of 126 patients in 6 centers completed the study. At the end of the 8th and 12th weeks, the mean number of inflammatory lesions reduced by 70.6% and 86.1%, non-inflammatory lesions by 81.5% and 92%, and total lesion count 75.6% and 88.8% respectively from baseline. Also, 90.7% and 93.6% of total study cases showed complete to moderate clearance of acne lesions according to physicians at the end of the 8th and 12th weeks. CONCLUSIONS: This study confirms the efficacy and safety of tazarotene gel (0.1%) in Indian patients of acne vulgaris.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow